ABSTRACT OBJECTIVE: The present study was designed to investigate the possible protection of pravastatin against hepatic oxidative stress and dysfunctions induced by doxorubicin in rats.
Introduction
The key public health concern around the world comes to cancer. There were about 8.2 million deaths in 2012 (1) . The most common treatment applied for cancer are radiation and chemotherapy. Despite antitumoral effects of these two therapeutic modalities in controlling the primary tumor and metastasis, toxicity can be produced in normal tissues by both of them and their associated adverse effects frequently outweigh clinical advantages and worsen patients' life quality (2) . During the past several decades, doxorubicin (DOX), which is also known as hydroxy daunorubicin, has been extensively applied for treating different cancer types such as hepatocellular carcinoma owing to its ability to kill transformed liver cells (3) . Liver injury is a moderately common adverse effect associated with DOX, which is observed in treating other cancer types by using this drug (4, 5) . Doxorubicin-induced hepatotoxicity has been reported in several experimental studies (6, 7) . The DOX toxicity mechanism comprised the oxidative stress status characterized by producing excessive amount of reactive oxygen species (ROS) and/or decrease in antioxidant defenses leading to a disbalance in the oxygen normal metabolism. First, a semiquinone form is generated as a result of adding an electron to the quinone moiety of DOX and then, the quinone form is quickly regenerated through reduction of molecular oxygen to ROS (8) . ROS produces hydrogen peroxide (H 2 O 2 ) and hydroxyl radicals (OH · ) and these products can attack DNA, oxidize it and fi nally induce apoptosis in both normal and tumoral tissue cells (9) . The other possible mechanism for DOX toxicity is via interference with non-enzymatic metabolic reactions that iron is involved in, and so the iron metabolism can be changed through this pathway. Consequently, DOX-iron complex can be formed through the reaction of free iron with DOX which leads to the formation of ROS (10) . Statins are extensively applied clinically to drop hypercholesterolemia due to their inhibitory impact on 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is a catalyst for the rate-limiting step in synthesizing the cholesterol in the liver and other tissues. Furthermore, the use of statins causes advantageous alterations in other lipid fractions as well as sig-nifi cant impacts on several measures of infl ammation, oxidative stress, immunity, vascular, thrombosis and renal function (11, 12) . In addition, small randomized controlled clinical trials have indicated advantageous impacts in non-cardiovascular infl ammatory diseases, including multiple sclerosis and rheumatoid arthritis (13) . No specifi c and effective therapeutic agent has been known for DOX-associated hepatotoxicity. Therefore, an urgent study is required to discover compounds with the ability to develop the chemotherapy therapeutic index and to decrease the side effects of DOX on healthy tissues with no effect on their anti-neoplasic impacts (2, 14, 15) . Hence, In the present study, we evaluated the content of tissue injury in DOX-induced hepatotoxicity and we evaluated the protective effect of pravastatin, especially, on the level of oxidative stress.
Materials and methods

Animals
Male Sprague-Dawley rats (190-200 g; n = 6 per group) were obtained from Animal House Center of Ahvaz Jundishapur University of Medical Sciences, Iran. The animals were housed in plastic cages and had free access to diet and tap water. The protocol of this study was approved by Ethics Committee of Ahvaz University of Medical Sciences. Rats were exposed to a 12-h light/dark cycle, at a room temperature of 22-25 °C.
Experimental design
The rats were divided into four groups: Group 1: Control rats given saline orally. Group 2: Rats administered with pravastatin orally with dose of 20 mg/kg for 15 days (16). Group 3: Rats given a single intraperitoneal injection of doxorubicin (15 mg /kg) (17). Group 4: Pravastatin (20 mg/kg, orally) given daily from 5 days prior to 10 days after intraperitoneal injection of doxorubicin. At the end of the experiment, the rats were weighed and then anaesthetized by ether. Blood samples were collected from the left ventricle and the sera were prepared following centrifuging at 2500 rpm for 20 minutes and kept frozen at -30 °C for various biochemical analyses. Also, the liver of each animal was rapidly removed after dissection. One part was fi xed in 10 % formalin for 72 hrs, and then transferred into 70 % alcohol for histopathological examination. An amount of 0.5 g was homogenized in 5 % (w/v) potassium phosphate buffer (0.1 M, pH 7.4) using a homogenizer (Heidolph Silentcrosher M, Germany). The liver homogenates were centrifugated at 16,000 × g for 20 min. The supernatants were used to estimation of biomarkers of oxidative stress.
Biochemical evaluation
Serum biomarkers of the liver function, including alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), TG (triglyceride), Chol (cholesterol), LDL (Lowdensity lipoprotein), HDL (high-density lipoprotein), albumin, and total bilirubin (TB) were measured using commercially available kits (Pars Azmoon, Iran). All biochemical assays were performed spectrophotometrically using an autoanalyzer (Vita lab Selectra E, Netherland).
Histopathological examinations
The liver samples were embedded in paraffi n and sectioned at 5 μm. After that, sections were stained with hematoxylin-eosin. Then, sections were examined under a light microscope. At least fi ve microscopic fi elds were evaluated to score the samples. The criteria for liver damage were dilatation of sinusoids, hepatocytes vacuolization and pyknotic hepatocyte nuclei. Each sample was scored by a scale ranging from 0 to 3 (0: none, 1: mild, 2: moderate, and 3: severe) for each criterion. The total score was 9. His- Tab. 1. Effect of pravastatin on biochemical parameters in doxorubicin-induced hepatotoxicity in rat.
topathological examination and scoring were carried out by an observer unaware of the experimental groups (18) .
Estimation of tissue lipid peroxidation
Tissue level of lipid peroxidase were determined by thiobarbituric acid reactive substances (TBARS) calculated as malondialdhyde (MDA) as described previously (19) . The absorbance was determined at 535 nm against a blank using spectrophotometer and the results were expressed as (nmol/g tissue).
Estimation of the antioxidant enzymes activities
Activity of endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) were assayed using the methods described in our previous study (20) . The results were expressed as U/g tissue.
Statistical analysis
All of the data are expressed as mean ± SD. Statistical significance between groups was tested using one-way ANOVA followed by the Tukey's test. The differences were considered statistically signifi cant when p < 0.05.
Results
Effect of pravastatin on ratio of liver weight to body weight
The ratio of liver weight to body weight in the group receiving DOX (group 3) signifi cantly increased compared to groups 1 and 2 (p < 0.001). The ratio of liver weight to body weight in group 4 was signifi cantly decreased compared with group 3 (p < 0.001). We did not observe any signifi cant differences between groups 1 and 2 (p > 0.05) (Fig. 1) .
Effect of pravastatin on biochemical parameters
DOX caused a signifi cant increase in serum ALT, AST, ALP, TG, Chol, LDL and TB levels as well as caused signifi cantly decrease in HDL and serum albumin levels when compared to groups 1 and 2 (p < 0.01). The treatment with pravastatin in group 4 markedly reversed DOX-induced increases in serum ALT, AST, TG, Chol, LDL and TB levels and the reduction in HDL and albumin levels (p < 0.01). These parameters in groups 1 and 2 were not signifi cantly different from each other (p > 0.05) (Tab. 1).
The effect of pravastatin on histological changes and microscopic score in liver
Light microscopic evaluation of liver tissues showed that there were no pathological changes in the liver tissue in groups 1 and 2 of animals ( Fig. 2 A and B) . In contrast, animals receiving DOX revealed mild to moderate pathological changes such as degeneration of hepatocyte cords, dilatation of sinusoids, vacuolation of hepatocytes and condensation of nuclei (Fig. 2 C) . Pravastatin treatment partially improved the hepatocyte cords degeneration, sinusoids, hepatocyte vacuolation which were morphologically near to control (Fig. 2 D) . As a result, the microscopic score of liver tissues of the DOX-injected group were signifi cantly higher than those of the groups 1 and 2 (p < 0.001). Pravastatin treatment diminished the microscopic score effectively (p < 0.001). There was no signifi cant difference between groups 1 and 2 (p > 0.05) (Tab. 2).
Effect of pravastatin on lipid peroxidation
MDA level was increased signifi cantly in the DOX -treated rats (Group 3) compared to groups 1 and 2 (p < 0.001). MDA level was decreased in the pravastatin + DOX-treated group (Group 4) compared to DOX-treated group (p < 0.001). However, MDA level in group 2 showed no difference compared to control group (p > 0.05) (Tab. 3).
Effect of pravastatin on antioxidant enzymes activities
Rats treated with DOX, showed a signifi cant reduction in activity of SOD, CAT and GPx compared to groups 1 and 2 (p <0.05). The treatment with pravastatin (Group 4) showed a signifi cant increase in SOD (p < 0.05), CAT (p < 0.001), GPx (p < 
Tab. 2. Effect of pravastatin on histopathological changes in doxorubicin-induced hepatotoxicity in rat.
0.05) activities as compared to Group 3. No difference was noticeable in antioxidant enzymes activity between groups 1 and 2 (p > 0.05) (Tab 3).
Discussion
The results of the current study indicate that daily pravastatin treatment of rats dramatically ameliorates DOX-induced hepatotoxicity as affi rmed by biochemical assays and microscopic evaluation. In present study, an increase in ratio of liver weight to body weight was observed in group 3. It might be because of body weight loss caused by the loss of skeletal muscles and adipose tissue that could have occurred due to appetite loss and alterations in the metabolic rates (21, 22) . However, a decrease in this ratio was observed for rats treated with pravastatin at the end of the period. These results are in accordance with earlier reports (23, 24) . The current results indicate that a signifi cant enhance in activities of ALT, AST, ALP and total bilirubin levels and a signifi cant reduction in serum albumin resulted from administration of DOX. The drastic conditions may have increased activities of ALT, AST and ALP and these conditions resulted from doxorubicin accumulations with toxic activity in the liver and in turn this might have provoked cellular destruction or rise in the hepatic cells permeability. The enhance in the level of total bilirubin may be ascribed to mechanisms of defense versus free radical-induced oxidative injury including decreasing free radicals through enhancing electron donors such as bilirubin (4) . The alterations, which are provided by DOX, are reversed by pravastatin treatment that shows the liver protective effect. The fi ndings of recent researches are the same as our results (11, 25) . Our results showed a signifi cant elevation in the serum concentration of TG, Chol and LDL in the group treated with DOX, but a reduction was observed for HDL concentration in this group. These variations in the profi le of lipid show that there is a possible interference of DOX with metabolism or biosynthesis of lipids (26) . The elevated serum concentrations of TG, Chol and LDL as well as the reduced concentrations of HDL were successfully restored by the pravastatin treatment. At least, there is one common feature for all statins despite their pharmacokinetic profi le differences: they prevent HMG-CoA converting to mevalonic acid by consecutive attenuation of the biosynthesis of cholesterol, which is related with a decrease in serum total and low-density lipoprotein (LDL) cholesterol. These features of statins are the reason of becoming the most extensively recommended lipid-lowering drugs in patients with raised serum cholesterol concentrations (27) . In the current research, severe liver damage is caused by injection of DOX, as evaluated microscopically. The morphology of hepatic tissue was recognized by vacuolation of hepatocytes, degenerated hepatocytes and moderate enlargement of sinusoids. In present study, it was also indicated that there is a signifi cant enhance in the MDA level and a reduction in the SOD, GPx and CAT activities as a result of the administration of DOX. The liver damage may take place because of the oxidative stress induced by the reactive intermediates of doxorubicin, namely semiquinone which generates from doxorubicin. The formation of radical intermediates of semiquinone by anthracyclines are reported. These radical intermediates react with molecular oxygen to form ROS which interact with cellular macromolecules and bring about cytological injury (28) . In an earlier research, it was proposed that doxorubicin raised MDA level (28) . In our fi ndings, a reduction in activities of SOD, GPx and CAT in the adriamycin-induced group may have taken place because of improved generation of ROS such as superoxide and hydrogen peroxide which in turn bring about antioxidant enzymes inhibition (29) . The treatment with pravastatin in part preserved the structural alterations resulting in morphology near to that of control group. Furthermore, we indicated that an elevation in the MDA level and reduction in the antioxidant enzymes activity after DOX injection was notably prevented by pravastatin. Statins are the most effective agents for dropping the cholesterol in plasma. They have also pleitropic non-lipid dependent properties, including antioxidant and anti-infl ammatory (30) . Moreover, the imbalance of oxidant-antioxidant is reversed by statins, which has a worthy activity of hydroxyl radical scavenging (31) . These results are in accordance with results of other studies (32) (33) (34) . In conclusion, pravastatin is helpful in doxorubicin-induced liver injury in rats and the mechanism of this effect may include preventing the peroxidation of lipid and preserving the antioxidant enzymes.
